Literature DB >> 2914407

Contrasting response to cyclosporin in refractory nephrotic syndrome.

R Zietse1, G J Wenting, P Kramer, P Mulder, M A Schalekamp, W Weimar.   

Abstract

We studied the effects of cyclosporin A (CsA), given for three months, in 14 patients with nephrotic syndrome refractory to treatment with prednisone and/or other immunosuppressants. CsA was given in a starting dose of 6 mg/kg and plasma through levels (RIA) were kept between 50 and 150 ng/ml. Diagnosis included: idiopathic membranous glomerulonephritis (n = 6), focal segmental glomerulosclerosis (n = 3), minimal change disease (n = 3) and membranoproliferative glomerulonephritis (n = 2). Three patients with non-immunologically mediated nephrotic syndrome due to Alport's syndrome were studied as well. Considering all patients and diagnostic groups together, proteinuria decreased from 9.0 +/- 4.3 to 4.7 +/- 3.8 g/24 h during CsA treatment (mean +/- SD; p less than 0.01). However, serum creatinine increased from 121.8 +/- 60.5 to 150.4 +/- 64.6 mol/l (p less than 0.01) and glomerular filtration rate as estimated by 24-hour creatinine clearance fell from 85.5 +/- 33.7 to 72.1 +/- 37.2 ml/min (p less than 0.05). When compared to other diagnostic groups, fractional excretion of protein, i.e. protein excretion corrected for changes in glomerular filtration rate, fell only in IMGN (ANOVA, p less than 0.05). We conclude that CsA reduced proteinuria in patients with refractory nephrotic syndrome. In the majority of these patients this reduction could be due to a renal hemodynamic, rather than an immunomodulatory effect of the drug. Only in IMGN the latter action of the drug may be of importance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914407

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience.

Authors:  M P Delaney; D C Dukes; M E Edmunds
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Focal segmental glomerulosclerosis complicating solitary kidney.

Authors:  Yoshiyuki Oshiro; Sachio Umena; Masatoshi Noda
Journal:  Clin Exp Nephrol       Date:  2008-08-09       Impact factor: 2.801

4.  Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome.

Authors:  R Elhence; S Gulati; V Kher; A Gupta; R K Sharma
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.